FEATURED PRODUCT
Deferoxamine-maleimide (B-772)
New for Cysteine Residue Conjugations
Macrocyclics introduced the first commercially available deferoxamine-based chelating agent designed specifically for use with 89Zr in 2008. The favorable 3-day half-life of this positron emitter has made it extremely popular for PET and molecular imaging applications with numerous studies demonstrating great potential for clinical applications. We are now proud to introduce our second generation bifunctional deferoxamine ligand system, B-772, designed for conjugations to cysteine residues.
New Developments
What’s in Store
Services
Bioconjugation Services
The staff at Macrocyclics has extensive experience in the field of bioconjugation and can provide cGMP production for phase I and phase II clinical studies.
> Read More
cGMP Services
Macrocyclics introduced its cGMP manufacturing services in 2005. Our quality system is designed specifically for the manufacture of APIs to be used in clinical trials.
> Read More
Consulting Services
The staff at Macrocyclics has an international reputation in the field of medical chelation chemistry.
> Read More
News & Events
04.11.2013
WIPR 2013 - Nantes, France
> Read More
01.08.2013
SNM - Society of Nuclear Medicine and Molecular Imaging - 2013
Visit Macrocyclics at Booth #1035
> Read More
07.27.2012
AREVA Med signs global partnership with Roche
"This major agreement with Roche is a remarkable milestone for nuclear medicine and radio-immunotherapy," said Patrick Bourdet, President and CEO of AREVA Med.
"Joining the core competencies of two global leaders in their respective fields will allow for the accelerated development of personalized, powerful and targeted treatments using Lead-212."
> Read More